Last updated: 2026-09-09 02:53:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
AN2 Therapeutics, Inc. (ANTX) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $5,97, with a market capitalization of $222,27M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1,00 to $7,19. This page covers its latest market performance, valuation, price trends and company information.
$222,27M | |
$6,00 | |
$64,78 | |
$0,87 | |
$5,89 | |
324,05K | |
286,21K | |
-- | |
$7,19 | |
$1,00 | |
-- | |
-- |
AN2 Therapeutics, Inc. (ANTX) last closed at $5,89 as of 2026-09-08 23:31:00, unchanged from the previous close of $5,89.
During the latest regular trading session, ANTX traded between $0,87 and $64,78, with a volume of 324,05K shares. The closing price was near the lower end and near the upper end of its 52-week range.
Over the past seven days, AN2 Therapeutics, Inc. (ANTX) moved from $5,74 to $5,97, representing a gain of 4,01% ($0,23).
The stock traded between $5,40 and $6,20 during the period. The latest price is near the upper end of the 7-day range, indicating moderate upward.
The average daily volume was 202,11 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 80,3%
ANTX is currently trading at $5,97, placing it 80,3% of the way from its 52-week low of $1,00 to its 52-week high of $7,19. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. Product candidate AN2-502998 Epetraborole.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 21 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of AN2 Therapeutics, Inc. (ANTX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.